Context Therapeutics Showcases CT-95 and CT-202 Initiatives at the 2025 SITC Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Should l Buy CNTX?
Source: Newsfilter
Context Therapeutics Overview: Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumors, with two key programs, CT-95 and CT-202, presented at the SITC 40th Annual Meeting.
CT-95 Program Details: CT-95 is a bispecific T cell engager targeting mesothelin, currently in a Phase 1 trial with promising safety data, and initial results are expected in mid-2026.
CT-202 Program Insights: CT-202 targets Nectin-4 and shows strong preclinical activity, with plans to initiate a first-in-human trial by the second quarter of 2026 following necessary regulatory filings.
Forward-Looking Statements: The company’s press release includes forward-looking statements regarding future operations and expectations, which involve risks and uncertainties that could affect actual outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CNTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CNTX
Wall Street analysts forecast CNTX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 2.590
Low
4.00
Averages
5.25
High
7.00
Current: 2.590
Low
4.00
Averages
5.25
High
7.00
About CNTX
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Context Therapeutics Reports Wider Losses in FY2025 and Pipeline Updates
- Financial Overview: Context Therapeutics reported a wider net loss of $36.13 million for FY2025, translating to a loss of $0.38 per share, compared to a loss of $26.73 million or $0.46 per share in 2024, indicating increased financial pressure that may affect future funding capabilities.
- Cash Position: As of December 31, 2025, the company had $66 million in cash and cash equivalents, which is expected to fund operations into mid-2027; while this provides a buffer, accelerating clinical trial progress is essential to boost market confidence.
- Clinical Trial Progress: The dose escalation trial for CTIM-76 is expected to complete in the first half of 2026, with plans to evaluate a three-week dosing regimen in the second half, which, if successful, could offer new treatment options in ovarian, endometrial, and testicular cancers.
- Future Plans: Context plans to present interim data for CTIM-76 and CT-95 in June and September 2026, respectively, and anticipates dosing the first patient in the CT-202 trial in Q3 2026, which could represent significant clinical milestones for the company.
See More
Context Therapeutics Reports FY GAAP EPS
- Financial Performance: Context Therapeutics reported a FY GAAP EPS of -$0.38, indicating significant challenges in financial performance that may affect investor confidence.
- Cash Flow Situation: As of December 31, 2025, the company's cash and cash equivalents stood at $66.0 million, a notable decline from $94.4 million on December 31, 2024, reflecting increased liquidity pressure.
- Historical Financial Data: According to Seeking Alpha's Quant Rating, the historical financial data for Context Therapeutics suggests ongoing issues with profitability and cash flow management, potentially impacting future financing capabilities.
- Market Reaction Outlook: Given the negative earnings report and declining cash flow, the market is expected to adopt a cautious stance towards Context Therapeutics' future prospects, which may lead to stock price volatility.
See More
Context Therapeutics Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: Context Therapeutics will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026, in New York, featuring 1x1 meetings aimed at enhancing the company's visibility among investors.
- Multiple Conference Participation: The company will also attend the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, in Boston, with a presentation scheduled for March 3, showcasing its innovations in the biopharmaceutical sector.
- Live Webcast and Replays: All presentations will be live-streamed on the company's website, with replays available for 90 days post-event, ensuring that investors unable to attend in person can access critical information, thereby enhancing transparency.
- Product Development Outlook: Context Therapeutics focuses on developing T cell engaging bispecific antibodies for solid tumors, and the upcoming conferences will provide a platform to showcase its candidates CTIM-76, CT-95, and CT-202, potentially attracting increased investor interest.
See More
Context Therapeutics Grants 120,000 Stock Options to Attract New Employees
- Employee Incentive Program: Context Therapeutics has granted a total of 120,000 non-qualified stock options to two new employees as an inducement for accepting employment, demonstrating the company's proactive strategy in talent acquisition.
- Option Grant Details: The stock options were granted at exercise prices of $1.47 and $1.49 per share, based on the closing prices on the grant dates, reflecting the company's confidence in its stock value.
- Long-Term Incentive Mechanism: The stock options have a 10-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in monthly installments, aimed at enhancing employee commitment and stability.
- Company Strategic Direction: Context Therapeutics focuses on developing T cell engaging bispecific antibodies for solid tumors, aiming to accelerate its innovative drug development process by attracting top talent, thereby enhancing its market competitiveness.
See More
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
- Alumis Clinical Progress: Alumis Inc. announced it will report topline data from its Phase 3 ONWARD clinical trial for moderate-to-severe plaque psoriasis on January 6, 2026, leading to a 17.33% stock surge, reflecting strong investor optimism ahead of the results.
- Genelux Trial Results: Genelux Corp. saw a 10.92% increase in share price following interim results from two ongoing trials, indicating that its Olvi-Vec may effectively resensitize tumors in small cell and non-small cell lung cancer patients, boosting market confidence in its product.
- Bright Minds Conference Announcement: Bright Minds Biosciences Inc. will host a conference call on January 6, 2026, to report results from its Phase 2 trial for drug-resistant absence seizures, with an 8.42% stock increase reflecting market anticipation for its findings.
- Alpha Tau FDA Submission: Alpha Tau Medical Ltd. submitted the first module of its pre-market approval application for Alpha DaRT to treat recurrent cutaneous squamous cell carcinoma, resulting in a 5.36% stock rise, as this modular approach may expedite the approval process and enhance market confidence.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
Context Therapeutics Reports Wider Losses in FY2025 and Pipeline Updates
- Financial Overview: Context Therapeutics reported a wider net loss of $36.13 million for FY2025, translating to a loss of $0.38 per share, compared to a loss of $26.73 million or $0.46 per share in 2024, indicating increased financial pressure that may affect future funding capabilities.
- Cash Position: As of December 31, 2025, the company had $66 million in cash and cash equivalents, which is expected to fund operations into mid-2027; while this provides a buffer, accelerating clinical trial progress is essential to boost market confidence.
- Clinical Trial Progress: The dose escalation trial for CTIM-76 is expected to complete in the first half of 2026, with plans to evaluate a three-week dosing regimen in the second half, which, if successful, could offer new treatment options in ovarian, endometrial, and testicular cancers.
- Future Plans: Context plans to present interim data for CTIM-76 and CT-95 in June and September 2026, respectively, and anticipates dosing the first patient in the CT-202 trial in Q3 2026, which could represent significant clinical milestones for the company.
See More
Context Therapeutics Reports FY GAAP EPS
- Financial Performance: Context Therapeutics reported a FY GAAP EPS of -$0.38, indicating significant challenges in financial performance that may affect investor confidence.
- Cash Flow Situation: As of December 31, 2025, the company's cash and cash equivalents stood at $66.0 million, a notable decline from $94.4 million on December 31, 2024, reflecting increased liquidity pressure.
- Historical Financial Data: According to Seeking Alpha's Quant Rating, the historical financial data for Context Therapeutics suggests ongoing issues with profitability and cash flow management, potentially impacting future financing capabilities.
- Market Reaction Outlook: Given the negative earnings report and declining cash flow, the market is expected to adopt a cautious stance towards Context Therapeutics' future prospects, which may lead to stock price volatility.
See More
Context Therapeutics Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: Context Therapeutics will participate in the Guggenheim Emerging Outlook: Biotech Summit on February 11-12, 2026, in New York, featuring 1x1 meetings aimed at enhancing the company's visibility among investors.
- Multiple Conference Participation: The company will also attend the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026, in Boston, with a presentation scheduled for March 3, showcasing its innovations in the biopharmaceutical sector.
- Live Webcast and Replays: All presentations will be live-streamed on the company's website, with replays available for 90 days post-event, ensuring that investors unable to attend in person can access critical information, thereby enhancing transparency.
- Product Development Outlook: Context Therapeutics focuses on developing T cell engaging bispecific antibodies for solid tumors, and the upcoming conferences will provide a platform to showcase its candidates CTIM-76, CT-95, and CT-202, potentially attracting increased investor interest.
See More
Context Therapeutics Grants 120,000 Stock Options to Attract New Employees
- Employee Incentive Program: Context Therapeutics has granted a total of 120,000 non-qualified stock options to two new employees as an inducement for accepting employment, demonstrating the company's proactive strategy in talent acquisition.
- Option Grant Details: The stock options were granted at exercise prices of $1.47 and $1.49 per share, based on the closing prices on the grant dates, reflecting the company's confidence in its stock value.
- Long-Term Incentive Mechanism: The stock options have a 10-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting in monthly installments, aimed at enhancing employee commitment and stability.
- Company Strategic Direction: Context Therapeutics focuses on developing T cell engaging bispecific antibodies for solid tumors, aiming to accelerate its innovative drug development process by attracting top talent, thereby enhancing its market competitiveness.
See More
Alumis Inc. (ALMS) Shares Surge 17.33% on Phase 3 Clinical Trial Data Announcement
- Alumis Clinical Progress: Alumis Inc. announced it will report topline data from its Phase 3 ONWARD clinical trial for moderate-to-severe plaque psoriasis on January 6, 2026, leading to a 17.33% stock surge, reflecting strong investor optimism ahead of the results.
- Genelux Trial Results: Genelux Corp. saw a 10.92% increase in share price following interim results from two ongoing trials, indicating that its Olvi-Vec may effectively resensitize tumors in small cell and non-small cell lung cancer patients, boosting market confidence in its product.
- Bright Minds Conference Announcement: Bright Minds Biosciences Inc. will host a conference call on January 6, 2026, to report results from its Phase 2 trial for drug-resistant absence seizures, with an 8.42% stock increase reflecting market anticipation for its findings.
- Alpha Tau FDA Submission: Alpha Tau Medical Ltd. submitted the first module of its pre-market approval application for Alpha DaRT to treat recurrent cutaneous squamous cell carcinoma, resulting in a 5.36% stock rise, as this modular approach may expedite the approval process and enhance market confidence.
See More
GH Research PLC Shares Surge 18.1% on FDA IND Status Update Announcement
- Significant Stock Surge: GH Research PLC shares rose 18.1% to $15.64 in pre-market trading, reflecting strong market anticipation for the upcoming update on its FDA IND status and Phase 3 program for GH001, which could pave the way for future drug approvals.
- Positive Market Reaction: As the company prepares to update its treatment plan for treatment-resistant depression, investor confidence in GH Research's prospects has significantly increased, potentially attracting more investors and enhancing the company's market valuation.
- Industry-Wide Impact: The progress of GH Research may not only boost its own stock price but also positively influence the entire biopharmaceutical sector, particularly in the treatment-resistant depression space, encouraging other companies to increase their R&D investments.
- Optimistic Future Outlook: With the FDA update on the horizon, GH Research is poised to gather more clinical data in the coming months, which will provide crucial support for its subsequent marketing and commercialization strategies, strengthening its position in the competitive pharmaceutical market.
See More
